Otezla works by inhibiting phosphodiesterase 4 (PDE4) intracellularly and has anti-inflammatory properties.1-4 By elevating cyclic adenosine monophosphate (cAMP) levels, Otezla is thought to indirectly modulate production of pro-inflammatory and anti-inflammatory mediators.3
Learn more about the role of phosphodiesterase 4 (PDE4) and cAMP in controlling inflammation.2-7View the PDE4 MOA
Learn how Otezla’s inhibition of PDE4 within cells affects the production of inflammatory mediators.1,3,4Review the Otezla MOA
The specific mechanism(s) by which Otezla exerts its therapeutic action in patients with psoriasis are not well defined.1
References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation. 2. Schafer PH, Parton A, Gandhi AK, et al. Br J Pharm. 2010;159(4):842-855. 3. Schafer PH, Parton A, Capone L, et al. Cell Signal. 2014;26(9):2016-2029. 4. Schafer P. Biochem Pharmacol. 2012;83(12):1583-1590. 5. Schett G, Sloan VS, Stevens RM, Schafer P. Ther Adv Musculoskelet Dis. 2010;2(5):271-278. 6. Gottlieb AB, Matheson RT, Menter A, et al. J Drugs Dermatol. 2013;12(8):888-897. 7. Moore AR, Willoughby DA. Clin Exp Immunol. 1995;101(3):387-389.
Indications & Important Safety Information
Please click here for Full Prescribing Information.
Do you wish to leave this site?
8 out of 10commercially insured lives in the US have preferred access with no biologic step required for Otezla® (apremilast)1